心肌重塑剂药理学研究的进展:十年的回顾
Jimin Liu1, Xiaqing Tian2, Meng Zhang3,4,5
1Innovation Research Institute of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Medicine
|June 9, 2025
概括
多组分药物通过协同向多个途径来治疗心肌重塑,显示出治疗心肌重塑的希望. 对这些药物的进一步研究可能会导致更有效的心血管疾病疗法.
科学领域:
- 心血管科学 心血管科学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 心肌重塑是心血管疾病的关键因素,如心力衰竭和心律失常.
- 了解其分子机制和药物点是至关重要的.
- 目前的方法侧重于单或多组分剂.
研究的目的:
- 探索多组分剂在心肌重塑中的潜力.
- 突出这些代理商的协同效应和挑战.
- 为心血管疾病提出新的药物开发途径.
主要方法:
- 对心肌重塑中的分子机制的审查.
- 对信号通路和关键"桥梁节点"的分析.
- 对多组分药物 (如Qili Qiangxin囊) 的临床试验数据的评估.
主要成果:
- 多组分剂可以通过调节多个信号分子来实现协同效应.
- 确定了关键的"桥梁节点"作为潜在的药物目标.
- 奇利辛囊示范了多组分药物开发的潜力.
结论:
- 多组分药物为心肌重塑提供了一个有前途的治疗策略.
- 克服识别化合物和机制的挑战是关键.
- 未来的研究应该专注于协同作用,多目标效应,以获得更安全,更有效的治疗方法.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
Heart Failure Drugs: Inotropic Agents
539
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
539
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
462
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
462
Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320
Antianginal Drugs: Nitrates and β-Blockers
540
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
540


